Amgen Faces $50.3M Verdict in Cancer Drug Patent Case

Amgen’s (AMGN.O), leukemia drug Blincyto infringes patents owned by Germany’s Lindis Biotech, a Delaware federal jury said in a verdict made public on Wednesday, awarding Lindis $50.3 million in damages.

The jury said that Amgen infringed two Lindis patents covering immunotherapy innovations. The verdict said Amgen’s infringement was willful, which could lead the court to increase the damages award up to $150.9 million.

Read more at Reuters.